Radiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers

Part of paid clinical trials in San Francisco, California.

Sponsor
University of California, San Francisco
Study ID
NCT04221893
Status
Recruiting
Apply to this trial

Conditions

  • Metastatic Anal Canal Carcinoma
  • Metastatic Colorectal Carcinoma
  • Metastatic Esophageal Carcinoma
  • Metastatic Gastric Carcinoma
  • Metastatic Gastroesophageal Junction Adenocarcinoma
  • Metastatic Hepatocellular Carcinoma
  • Metastatic Malignant Digestive System Neoplasm
  • Metastatic Small Intestinal Carcinoma
  • Pancreatobiliary Carcinoma
  • Pathologic Stage IV Gastric Cancer AJCC v8
  • Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8
  • Pathologic Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8
  • Pathologic Stage IVB Esophageal Adenocarcinoma AJCC v8
  • Pathologic Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8
  • Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8
  • Postneoadjuvant Therapy Stage IV Esophageal Squamous Cell Carcinoma AJCC v8
  • Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8
  • Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8
  • Postneoadjuvant Therapy Stage IVA Esophageal Adenocarcinoma AJCC v8
  • Postneoadjuvant Therapy Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8
  • Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8
  • Postneoadjuvant Therapy Stage IVB Esophageal Adenocarcinoma AJCC v8
  • Postneoadjuvant Therapy Stage IVB Esophageal Squamous Cell Carcinoma AJCC V8
  • Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8
  • Stage IV Adenocarcinoma of the Gastroesophageal Junction
  • Stage IV Anal Cancer AJCC v8
  • Stage IV Colorectal Cancer AJCC v8
  • Stage IV Esophageal Adenocarcinoma
  • Stage IV Esophageal Squamous Cell Carcinoma
  • Stage IV Gastric Cancer
  • Stage IV Hepatocellular Carcinoma AJCC v8
  • Stage IVA Adenocarcinoma of the Gastroesophageal Junction
  • Stage IVA Colorectal Cancer AJCC v8
  • Stage IVA Esophageal Adenocarcinoma
  • Stage IVA Esophageal Squamous Cell Carcinoma
  • Stage IVA Gastric Cancer
  • Stage IVA Hepatocellular Carcinoma AJCC v8
  • Stage IVB Colorectal Cancer AJCC v8
  • Stage IVB Esophageal Adenocarcinoma
  • Stage IVB Esophageal Squamous Cell Carcinoma
  • Stage IVB Gastric Cancer
  • Stage IVB Gastroesophageal Junction Adenocarcinoma
  • Stage IVB Hepatocellular Carcinoma AJCC v8
  • Stage IVC Colorectal Cancer AJCC v8

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Radiation Therapy (RT) — RADIATION
    Undergo radiation therapy

Study Details

This phase II trial studies how well radiation therapy works for the treatment of gastrointestinal cancer that are spreading to other places in the body (metastatic). Radiation therapy uses high energy x-rays to kill cancer cells and shrink tumors. This trial is being done to determine if giving radiation therapy to patients who are being treated with immunotherapy and whose cancers are progressing (getting worse) can slow or stop the growth of their cancers. It may also help researchers determine if giving radiation therapy to one tumor can stimulate the immune system to attack other tumors in the body that are not targeted by the radiation therapy.

Key Dates

Start date
Aug 7, 2020
Status verified
Sep 2025
Primary completion
Jun 30, 2026
Completion
Apr 30, 2028

Study Design

Enrollment
28 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Radiation therapy (RT)
    Patients undergo radiation therapy for a total of 5 treatments over 5-9 calendar days in the absence of disease progression or unacceptable toxicity. Target prescription dose will be 30 Gy in 5 fractions and each treatment site (up to 5) will undergo standard Department-approved treatment planning, quality-assurance, and delivery protocols

Primary Outcome Measure

Overall response rate (ORR) [ Time Frame: Up to 8 weeks ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
University of California, San FranciscoSan FranciscoCalifornia94143
Luchia Andemicael
[email protected]
415-530-9814
[email protected]
877-827-3222
Mary Feng, MD (PRINCIPAL_INVESTIGATOR)
John Muir Medical Center-Walnut CreekWalnut CreekCalifornia94598
Sravan Chennupati, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in San Francisco, CA

By research site
University of California, San Francisco· San Francisco, CAJohn Muir Medical Center-Walnut Creek· Walnut Creek, CA

Related Studies